CTOs on the Move

Abata Therapeutics

www.abatatx.com

 
We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. We are bold in our mission and purpose and aim for nothing less than ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.abatatx.com
  • 245 First Street
    Cambridge, MA USA 02142
  • Phone: 929.463.4100

Executives

Name Title Contact Details

Similar Companies

Rockland Immunochemicals

Rockland Immunochemicals is a Gilbertsville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biomerieux

Biomerieux is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lower Valley Ambulance

Lower Valley Ambulance is a Cheswick, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zygote

Zygote is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Better Therapeutics

Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.